Colorectal cancer survival gains and novel treatment regimens a systematic review and analysis

JAMA Oncology

Volumn 1, Issue 6, 2015, Pages 787-795

  Jawed, Irfan ^a,b   Wilkerson, Julia ^a   Prasad, Vinay ^a   Duffy, Austin G ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Lawrence Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLORECTAL NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; FORECASTING; HUMAN; METASTASIS; MORTALITY; ONCOLOGY; PATHOLOGY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TIME; TREATMENT OUTCOME; TRENDS;

COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FORECASTING; HUMANS; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84965091712     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1790     Document Type: Article

References (25)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF. SEER Cancer Statistics Review, 1975-2009, (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2012.
2. Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005;16(3):425-429.
3. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27 (22):3677-3683.
4. Wilkerson J, Fojo T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J. 2009;15(5):379-385.
5. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26): 2666-2676.
6. Bendell JC, Bekaii-Saab TS, Cohn AL, et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012;17(12):1486-1495.
7. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22 (7):1209-1214.
8. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist. 2000;5(1): 26-35.
9. Roché H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol. 2011;22(5):1000-1010.
10. National Cancer Institute. Cancer Screening Overview (PDQ®): lead time bias: does screening help people live longer? http://www.cancer.gov/about-cancer/screening/patient-screening-overview-pdq#section/all. Accessed March 23, 2015.
11. Kramer BS. The science of early detection. Urol Oncol. 2004;22(4):344-347.
12. Shi Q, Andre T, Grothey A, et al. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. J Clin Oncol. 2013;31(29):3656-3663.
13. Selvaggi F, Cuocolo A, Sciaudone G, Maurea S, Giuliani A, Mainolfi C. FGD-PET in the follow-up of recurrent colorectal cancer. Colorectal Dis. 2003;5 (5):496-500.
14. Gearhart SL, Frassica D, Rosen R, Choti M, Schulick R, Wahl R. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol. 2006;13(3):397-404.
15. McDermott PW. Industry perspective on clinical investigative sites: maximizing sponsor return on investment. http://digitalcommons.hsc.unt.edu/theses/93. Accessed May 1, 2015.
16. American Cancer Society. Treatment of colon cancer by stage. http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-treating-by-stage-colon. Accessed May 1, 2015.
17. Cancer Research UK. Which treatment for advanced bowel cancer. http://www.cancerresearchuk.org/about-cancer/type/bowel-cancer/treatment/types/which-treatment-for-advanced-bowel-cancer. Accessed May 1, 2015.
18. Memorial Sloan Kettering Cancer Center. Colorectal Cancer: Treatment for Metastases. https://www.mskcc.org/cancer-care/adult/colorectal/treatment-metastases. Accessed May 1, 2015.
19. Bartlett EK, Simmons KD, Wachtel H, et al. The rise in metastasectomy across cancer types over the past decade. Cancer. 2015;121(5):747-757.
20. Barton MK. Metastasectomy on the rise across several cancer types. CA Cancer J Clin. 2015;65(3): 163-164.
21. Marshall JL, Cartwright TH, Berry CA, Stowell SA, Miller SC. Implementation of a performance improvement initiative in colorectal cancer care. J Oncol Pract. 2012;8(5):309-314.
22. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol. 2005; 23(34):8664-8670.
23. Buyse M, Burzykowski T, Michiels S, Carroll K. Individual-and trial-level surrogacy in colorectal cancer. Stat Methods Med Res. 2008;17(5):467-475.
24. Elston J, Taylor RS. Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom health technology assessment reports. Int J Technol Assess Health Care. 2009;25(1):6-13.
25. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431-440.